Study Identifies Stabilizing Bonds as Key to Stability Range in Disordered Solids
A research paper published on 31 May 2026 examines how specific particle interactions determine stability levels in disordered solids. The work spans materials from marginally stable to ultra-stable states.
3dprintingindustry.comA paper published 31 May 2026 identifies stabilizing bonds—interactions whose removal would cause mechanical failure—as a structural feature that governs stability in disordered solids. The study shows these bonds recover the weak force distribution predicted by existing theories and can forecast failure under load.
Researchers tracked how the number, arrangement, and unstable modes of these bonds change as materials move from marginal to ultra-stable states.
The authors report that stabilizing bonds function as defects whose spatial organization influences overall mechanical response. Materials with fewer or differently distributed stabilizing bonds exhibited higher stability under applied stress. The analysis links bond-level properties directly to the spectrum of observed stabilities without relying on bulk structural metrics.
The findings establish stabilizing bonds as a measurable indicator for predicting when disordered solids will fail. The approach applies across glasses and other disordered systems where conventional order parameters are absent. Further work may use stabilizing-bond counts to design materials with targeted mechanical lifetimes.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
Ebola Cases in Central Africa Rise from 256 to About 1,000 in Eleven Days
Suspected and confirmed Ebola cases in the Democratic Republic of the Congo and Uganda increased from 256 on 16 May to roughly 1,000 by 27 May. The World Health Organization reported about 240 deaths during the same period.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.